NCT03183570View on ClinicalTrials.gov

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

November 8, 2017

Primary Completion Date

April 25, 2023

Study Completion Date

January 25, 2025

Conditions

Idiopathic Pulmonary FibrosisPrimary Sclerosing CholangitisCovid19 Pneumonia

Interventions

DRUG

[18F]FP-R01-MG-F2

7mCi (range 6-9mCi) \[18F\]FP-R01-MG-F2 will be administered

Trial Locations (1)

94305

Stanford University, Stanford

Sponsors

Collaborators (1)

Pliant Therapeutics, Inc.

All Listed Sponsors

collaborator

Pliant Therapeutics, Inc.

INDUSTRY

lead

Stanford University

OTHER

NCT03183570 - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT | Biotech Hunter | Biotech Hunter